Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD5069 + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD5069||AZD-5069|AZD 5069||CXCR Antagonist 4||AZD5069 binds to and inhibits CXCR2 signaling, resulting in reduced neutrophil chemotaxis (PMID: 25736418, PMID: 29856004).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 107||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02499328||Phase Ib/II||AZD9150 + Durvalumab AZD5069 + Durvalumab Durvalumab AZD9150||Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck||Active, not recruiting||USA | ITA | GBR | ESP | DEU | BEL||0|
|NCT02583477||Phase Ib/II||AZD5069 + Durvalumab Durvalumab + Gemcitabine + Nab-paclitaxel||Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma||Completed||USA | GBR||0|